Dr. Stan Wang,
Non-Resident Senior Fellow, Council on Strategic Risks

Dr. Stan Wang is a Non-Resident Senior Fellow with the Council on Strategic Risks. From medicine, science, to entrepreneurship, Dr. Stan Wang is driven by the possibility of bringing novel life-changing treatments to patients in need. As Founding CEO of Thymmune Therapeutics, he is pioneering an innovative cell therapy approach to addressing unmet needs across immunology. Previously, Stan was Founding CSO at Cellino Biotech. As a CSR Non-Resident Senior Fellow, Dr. Wang is passionate about making bioweapons obsolete through universal pathogen identification, tracking, and prediction, along with ensuring that rapid advances in and the increasing accessibility of biotechnology are applied safely and efficaciously.

Dr. Wang received his PhD from the University of Cambridge as a Gates Scholar and NIH-Cambridge MD/PhD Scholar. For his thesis, he worked on stem cell biology and regenerative medicine with John Gurdon and Roger Pederson at Cambridge (UK), along with Vittorio Sartorelli at NIH (US). Dr. Wang received his MD from Columbia University via the NIH Medical Scientist Training Program. He was a postdoctoral fellow with George Church at Harvard Medical School.